Brief: Neonc Technologies Reports Phase 1 Dose-Escalation Results For Dosing And Toxicity And Determination Of Recommended Phase 2 Dose For Oral Neo212 Management To Host Kol Conference Call Today At 9 A.M. Et

Neonc Technologies Holdings

04/03/2026 13:04

March 4 (Reuters) - Neonc Technologies Holdings Inc NTHI.O:

NEONC TECHNOLOGIES REPORTS PHASE 1 DOSE-ESCALATION RESULTS FOR DOSING AND TOXICITY AND DETERMINATION OF RECOMMENDED PHASE 2 DOSE FOR ORAL NEO212; MANAGEMENT TO HOST KOL CONFERENCE CALL TODAY AT 9 A.M. ET

NEONC TECHNOLOGIES HOLDINGS INC - RECOMMENDED PHASE 2 DOSE FOR NEO212 SET AT 610 MG

NEONC TECHNOLOGIES HOLDINGS INC - TO REQUEST TYPE B FDA MEETING FOR NEO212 PHASE 2 REVIEW

NEONC TECHNOLOGIES HOLDINGS INC - PHASE 2A METASTASIS COHORT STARTING DOSE FOR NEO212 WILL BE 400 MG

NEONC TECHNOLOGIES HOLDINGS INC - PHASE 1 SHOWS MEASURABLE ANTI-TUMOR ACTIVITY FOR NEO212

Source text: ID:nGNX7Zpx2H

Further company coverage: NTHI.O

 ((Reuters.Briefs@thomsonreuters.com;))